Virology Journal

Overview

publication venue for

• Parvovirus B19 integration into human CD36+ erythroid progenitor cells.  511:40-48. 2017
• HTLV-1 Tax activates HIV-1 transcription in latency models.  504:45-51. 2017
• Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies.  494:236-47. 2016
• Limited variation during circulation of a polyomavirus in the human population involves the COCO-VA toggling site of Middle and Alternative T-antigen(s).  487:129-40. 2016
• Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers.  486:116-120. 2015
• Pneumolysin expression by streptococcus pneumoniae protects colonized mice from influenza virus-induced disease.  462-463:254-65. 2014
• Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus.  444:140-7. 2013
• The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients.  444:292-300. 2013
• Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.  428:86-97. 2012
• V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.  427:158-65. 2012
• Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.  422:22-36. 2012
• Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.  413:47-59. 2011
• Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function.  401:236-47. 2010
• Glycoprotein D actively induces rapid internalization of two nectin-1 isoforms during herpes simplex virus entry.  399:109-19. 2010
• Serotype 5 Adenovirus fiber (F7F41S) chimeric vectors incur packaging deficiencies when targeting peptides are inserted into Ad41 short fiber.  395:10-20. 2009
• Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.  389:108-21. 2009
• Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.  387:296-302. 2009
• Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins.  385:275-81. 2009
• Putative gene promoter sequences in the chlorella viruses.  380:388-93. 2008
• Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.  378:79-85. 2008
• Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.  377:401-407. 2008
• The herpes simplex virus receptor nectin-1 is down-regulated after trans-interaction with glycoprotein D.  373:98-111. 2008
• N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.  372:187-200. 2008
• Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.  369:245-62. 2007
• Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.  364:281-90. 2007
• Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.  364:431-40. 2007
• Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Δ32 heterozygote.  362:163-78. 2007
• HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.  361:212-28. 2007
• A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.  360:329-40. 2007
• Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.  360:199-208. 2007
• Genetic analysis of poxvirus mRNA cap methyltransferase: Suppression of conditional mutations in the stimulatory D12 subunit by second-site mutations in the catalytic D1 subunit.  352:145-56. 2006
• Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex.  351:121-32. 2006
• Interaction of small molecule inhibitors of HIV-1 entry with CCR5.  349:41-54. 2006
• CD8 T cell effector maturation in HIV-1-infected children.  347:117-26. 2006
• Use of alternate coreceptors on primary cells by two HIV-1 isolates.  339:136-44. 2005
• Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).  338:182-99. 2005
• The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles.  338:154-72. 2005
• Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability.  337:136-48. 2005
• Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein.  335:34-45. 2005
• Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses.  328:19-29. 2004
• Complete genomic DNA sequence of rock bream iridovirus.  325:351-63. 2004
• The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.  321:8-22. 2004
• Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection.  313:147-57. 2003
• Amino acid substitutions within the heptad repeat domain 1 of murine coronavirus spike protein restrict viral antigen spread in the central nervous system.  312:369-80. 2003
• Expression of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor monocistronic and bicistronic transcripts in primary effusion lymphomas.  287:62-70. 2001
• A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1.  280:292-300. 2001
• Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects.  279:459-70. 2001
• Direct measurement of CD8+ T cell responses in macaques infected with simian immunodeficiency virus.  272:347-56. 2000
• Characterization of HIV-1-specific cytotoxic T lymphocytes expressing the mucosal lymphocyte integrin CD103 in rectal and duodenal lymphoid tissue of HIV-1-infected subjects.  270:317-27. 2000
• Passive infusion of immune serum into simian immunodeficiency virus- infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia.  270:237-249. 2000
• Creation and repair of specific DNA double-strand breaks in vivo following infection with adenovirus vectors expressing Saccharomyces cerevisiae HO endonuclease.  266:211-24. 2000
• Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine.  266:203-10. 2000
• Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase.  263:307-12. 1999
• Interactions among HIV gp120, CD4, and CXCR4: Dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies.  248:394-405. 1998
• Altered pathogenesis of a mutant of the murine coronavirus MHV-A59 is associated with a Q159L amino acid substitution in the spike protein.  239:1-10. 1997
• Syncytia formation induced by coronavirus infection is associated with fragmentation and rearrangement of the Golgi apparatus.  221:325-34. 1996
• HIV-1 infection of cultured human adult oligodendrocytes.  217:211-9. 1996
• Role of glucocorticoid receptor binding sites in the human immunodeficiency virus type 1 long terminal repeat in steroid-mediated suppression of HIV gene expression.  214:512-21. 1995
• Intracerebral Hemorrhages and Infarction Induced by a Murine Leukemia Virus Is Influenced by Host Determinants within Endothelial Cells.  203:393-6. 1994
• MHV-A59 fusion mutants are attenuated and display altered hepatotropism.  200:1-10. 1994
• A model system for regulation of chronic HIV-1 infection in peripheral B lymphocytes.  196:433-41. 1993
• An immune-selected point mutation in the transmembrane protein of n immunodeficiency virus type 1 (HXB2-Env:Ala 582(→ Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.  196:332-7. 1993
• A spleen necrosis virus-based retroviral vector which expresses two genes from a dicistronic mRNA.  186:669-75. 1992
• CPF-DD is an inhibitor of infection by human immunodeficiency virus and other enveloped viruses in vitro.  188:537-544. 1992
• Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.  189:695-714. 1992
• Early events in Epstein-Barr virus genome expression after activation: Regulation by second messengers of B cell activation.  185:922-8. 1991
• Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in Vitro.  185:72-9. 1991
• Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2.  180:853-6. 1991
• Vaccinia virus induces cell fusion at acid ph and this activity is mediated by the N-terminus of the 14-kDa virus envelope protein.  178:81-91. 1990
• Activation of the major late promoter in adenovirus transformed cells by 5-azacytidine.  165:296-8. 1988
• Homologous recombination between hepadnaviral genomes following in Vivo DNA transfection: Implications for studies of viral infectivity.  159:454-6. 1987
• Effect of primary amines on interferon action.  117:510-5. 1982
• Analysis of endogenous avian retrovirus DNA and RNA: Viral and cellular determinants of retrovirus gene expression.  114:8-22. 1981
• Repair of lesions which cause premature termination of transcription in chicken embryo cells irradiated with ultraviolet light.  112:752-6. 1981
• The genesis of rous sarcoma virus messenger RNAs.  112:714-28. 1981
• Cell-free translation of purified avian sarcoma virus src mRNA.  110:476-8. 1981
• Endogenous proviruses of random-bred chickens and ring-necked pheasants: Analysis with restriction endonucleases.  108:222-9. 1981
• Integration of avian sarcoma virus DNA in chicken cells.  108:208-21. 1981
• Organization of the endogenous proviruses of chickens: Implications for origin and expression.  108:189-207. 1981
• Restriction endonuclease mapping of the DNA of Rous-Associated virus 0 reveals extensive homology in structure and sequence with avian sarcoma virus DNA.  108:177-88. 1981
• Revertants of an ASV-transformed rat cell line have lost the complete provirus or sustained mutations insrc.  108:28-46. 1981
• The structure and protein kinase activity of proteins encoded by nonconditional mutants and back mutants in thesrc gene of avian sarcoma virus.  108:47-70. 1981
• Two cellular proteins that immunoprecipitate with the transforming protein of Rous sarcoma virus.  113:736-51. 1981
• The vertebrate homology of the putative transforming gene of avian myelocytomatosis virus: Characteristics of the DNA locus and its RNA transcript.  105:415-24. 1980
• Conformation of free and of integrated Moloney leukemia virus proviral DNA in preleukemic and leukemic BALB/Mo mice.  101:111-23. 1980
• DNA of a chicken herpesvirus is associated with at least two chromosomes in a chicken lymphoblastoid cell line.  105:234-40. 1980
• Identification and characterization of dimeric and trimeric circular forms of avian sarcoma virus-specific DNA.  103:425-33. 1980
• Transformation-related proteins associated with Kirsten sarcoma virus.  106:335-48. 1980
• Mutants of rous sarcoma virus with extensive deletions of the viral genome.  96:530-46. 1979
• Endogenous mouse mammary tumor virus DNA is distributed among multiple mouse chromosomes.  92:46-55. 1979
• Maturation of the head of bacteriophage T4: 9-aminoacridine blocks a late step in DNA packaging.  92:219-29. 1979
• Characterization of a defective pseudotype particle of Kirsten sarcoma virus.  95:536-49. 1979
• The replication of subgroup E avian retroviruses is blocked at or before viral DNA synthesis in restrictive chicken cells.  99:437-42. 1979
• Characterization of dna complementary to nucleotide sequences adjacent to poly(A) at the 3′-terminus of the avian sarcoma virus genome.  79:183-97. 1977
• Characterization of dna complementary to nucleotide sequences at the 5′-terminus of the avian sarcoma virus genome.  79:198-215. 1977
• Biological and biochemical studies on the inactivation of avian oncoviruses by ultraviolet irradiation.  77:689-704. 1977
• Characteristics of virus-specific RNA in avian sarcoma virus-transformed BHK-21 cells and revertants.  76:313-30. 1977
• Detection and enumeration of transformation-defective strains of avian sarcoma virus with molecular hybridization.  76:675-84. 1977
• Characterization of "early" temperature-sensitive mutants of avian sarcoma viruses: Biological properties, thermolability of reverse transcriptase in vitro, and synthesis of viral DNA in infected cells.  74:16-29. 1976
• Differences between genomes of two strains of mouse mammary tumor virus as shown by partial RNA sequence analysis.  72:330-40. 1976
• Nucleotide sequence homologies among mouse mammary tumor viruses.  70:550-3. 1976
• Production of mouse mammary tumor virus by cultured cells in the absence and presence of hormones: Assay by molecular hybridization.  65:135-47. 1975
• Characterization of the nucleic acid product of the visna virus RNA dependent DNA polymerase.  57:251-8. 1974
• Homologies among the nucleotide sequences of the genomes of C-type viruses.  58:568-75. 1974
• Serological analysis of reverse transcriptase of the Mason-Pfizer monkey virus.  59:335-8. 1974
• The importance of DNA size for successful transfection of chicken embryo fibroblasts.  61:297-302. 1974
• The persistence and expression of virus-specific DNA in revertants of Rous sarcoma virus-transformed BHK-21 cells.  62:512-21. 1974
• RNA-directed DNA synthesis by virions of Rous sarcoma virus: Further characterization of the templates and the extent of their transcription.  52:264-74. 1973
• Role of dna genes of Escherichia coli in M13 phage replication.  52:417-24. 1973
• Inhibition of M13 phage synthesis by rifampicin in some rifampicin-resistant Escherichia coli mutants.  50:422-30. 1972
• Corrigendum to "V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc" [Virology 427 (2012) 158-165].  428:76-83. 2012
• Broadly neutralizing antibodies against HIV-1: Templates for a vaccine 2013
• Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects? 2004

Identity

ISO Abbreviation

• Virology

Linking ISSN

• 0042-6822

International Standard Serial Number (ISSN)

• 0042-6822

Electronic International Standard Serial Number (EISSN)

• 1096-0341